Who invested in Neurelis

3 rounds we have observed, with the 0 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Pharma

Follow Neurelis and see its new rounds in your feed.Start following

Funding summaryUpdated 31 Oct 2026

$4.3Mraised across 3 rounds since 2010, from 3 sources

$1.7MDebt$1.1MDebt$1.5MVenture

Latest round: Venture, $1.5MJul 2015
Biggest round: $1.7MDebt · Feb 2010
Step-upi: 1.4×
Investors: 0

See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

201020112012201320142015

$1.7MDebt$1.1MDebt$1.5MVenture

First round: Debt, $1.7M
Biggest round: $1.7M
Usual gap between rounds: 3.8 years

The rounds

Jul 2015
Venture$1.5M
No investor was named in the report.
From a historical funding recordSEC filing: $1.5M sold, first sale Jul 2015
Oct 2011
Debt$1.1M
No investor was named in the report.
Reported by sec.govSEC filing: $1.1M sold, first sale Sept 2011
Feb 2010
Debt$1.7M
No investor was named in the report.
Reported by sec.govSEC filing: $1.7M sold, first sale Jan 2010

Founders and team

From Neurelis's own website and the SEC filings it signed: 1 founder, 3 on the team.

Craig C. ChamblissPresident and CEO/Co-FounderNamed on its 2021 Form D

Chuck DeWildtChief Commercial Officer
Jenny AlonsoGeneral Counsel and Chief Compliance Officer
George F. StuartExecutive Officeri

On the board, as filediDavid F. HaleHuaizheng C. PengKevin C. LiPriyanka F. BelawatStephen F. Cartt

The exit

ExitBuyerPriceWhen

AcquiredBiotie TherapiesundisclosedJun 2013

From historical deal records. Wrong? Tell us.

Also claim to have backed them

This firm lists Neurelis as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.